Part 2 of the Cholesterol Conspiracy Mini-Series. Click here for Part 1.
So, you walk into your doctor’s office for something totally unrelated — a sore knee, maybe a refill on your blood pressure meds, maybe just to show off that new tattoo. You haven’t even sat down yet, and before you can say ‘hello,’ your doctor is already scribbling away on the prescription pad.
And what is it this time? Surprise! It’s a statin.
Why? Because your labs came back already? And your LDL is ‘a little high.’ Because you’re over 50? Because – well, honestly – because breathing after 40 apparently requires a statin in modern medicine? I’m pretty sure they’ll be recommending them for toddlers any day now, just to be safe. PS: The pediatricians already are.
If you happen to have been living under a rock for the past 50 years, statins are the most profitable drug class in all of human history. Like ever. That’s right, folks – we’re talking about the literal Golden Goose of Big Pharma, laying billion-dollar eggs year after year. Like hundreds of billions. People line up like livestock, taking prescriptions from doctors in their left hand, passing them over to their pharmacists in the right – statin script after statin script heading from the front door of Walgreens to the back door of the American household in revolving door style fashion. But crack that shiny golden goose egg shell open, and what you find inside is… well, not the billion-dollar diamond you were thinking it might be.
Industry-funded studies have been spun to make statins look like miracle drugs, while burying side effects and inflating benefits with what might be described as straight-up medical misinformation math magic. Allegedly. More recently, a massive 2022 meta-analysis (using mostly industry-funded trials) attempting to put a nail in the coffin of statin benefit doubt, showed their actual benefits are about as underwhelming as a virgin tequila shot. Lord.
So with all the damning and revealing data showing harms, and the thready, industry-funded data straining hard to show “benefit”, why are statins still being handed out like candy? Have doctors and scientists forgotten how to read? How to credibly dissect “research”? Why does it feel like this class of medications is the only tool conventional medicine has left for prevention of heart disease?
I’ll tell you why: because the fear over dietary fat and cholesterol was the setup, statins were the big payoff, and Industry has been laughing all the way to the bank ever since.
I’m Dr. Kristen Lindgren, and welcome back to The Dysfunction Files. Last week, in Episode 21, we pulled apart the cholesterol myth. This week, we’re looking at the so-called solution that followed: statins – Big Pharma’s Golden Goose. Not to wreck the punchline, but spoiler alert – it’s not about saving lives – it’s about selling you a lifetime subscription. And hopefully nothing darker than that. What we’ve been told about the benefits of statin medications may be the biggest sleight of hand Big Pharma has ever played.
Let’s get into it.
The Rise of the Golden Goose
We all know statins are everywhere. But the better question is why? And how? How did they become the single most prescribed drug class in human history?
To answer that, let’s take the Wayback Machine all the way back to 1913. Enter Nikolai Anichkov, a Russian scientist who decided the best way to understand heart disease was to… wait for it… force-feed rabbits a diet made entirely of cholesterol.
Quick biology refresher: rabbits are herbivores. They don’t eat cholesterol unless they happen to be hooked up to an IV of it in a lab. Their normal diet is salad. But apparently when you force feed them 100% cholesterol they do in fact develop a kind of ‘atherosclerosis’. Anichkov patted himself of the back, declared cholesterol caused vascular disease and that was that. Never mind that the plaque looked nothing like atherosclerotic plaque we see in humans, and never mind that rabbits are rabbits and not humans. None of that mattered. The seed was planted: cholesterol was declared the villain, and we were off to the races.
This birthed the infamous “Lipid-Heart Hypothesis” – the idea that dietary fat and cholesterol cause heart disease. And like all good myths, it stuck. I get it – I have a tin foil hat. I’d need several to follow this literal rabbit hole, but whatever – let’s stay on track.
Fast-forward to 1955. On the world’s stage, President Eisenhower suffers a heart attack. Suddenly, heart disease isn’t just a scientific debate – it’s front-page news. Panic ensues, and the cholesterol causes heart disease hypothesis went from lab curiosity to national gospel.
Drug companies smelled opportunity. How could you blame them? The William S. Merrell Company rolled out a drug called Triparanol in 1959, the first cholesterol-lowering medication to hit the market. Commercial success followed – until it didn’t. By 1962, it was yanked after causing severe and permanent side effects – you know, like blinding cataracts, hair loss, skin ulceration, liver failure. Oh, and the best part? It actually accelerated atherosclerosis, the very thing it was supposed to prevent. Well, Scrap that version.
Undeterred, Pharma kept racing.
By the mid-1970s, the statin race was on. In Japan, Akira Endo at Sankyo Pharmaceuticals discovered compactin (also called mevastatin), the very first statin, isolated from a mold. In animal studies, it was wildly effective at lowering cholesterol – but then, Sankyo scientists noticed gastrointestinal tumors popping up in the dogs given mevastatin. They gave statins to dogs?? Why – just why. They panicked, shelved the project, and decided statins were too dangerous to continue. The Japanese tapped out.
Meanwhile, Merck was watching closely. They had their own fungal derivative in the works – lovastatin. And instead of pulling the plug, Merck shrugged off the cancer concerns as “species-specific.” Dogs aren’t people; only dogs will get tumors. Proceed.
By 1987, the FDA approved Merck’s lovastatin, and the marketing floodgates were opened. Overnight, cholesterol wasn’t just a number on your lab slip – it was a death sentence. You don’t want to be subject to the same fate as the president, do you? Of course not. The solution? A daily pill, for life. Here – take this lovastatin. Just don’t give it to your dog.
Not everyone was fully convinced, though. In 1990, the NIH convened a panel to ask a very logical but uncomfortable question: could lowering cholesterol actually be dangerous? The panel admitted… yeah, it might be. But did that slow the train? Please.
By 2001, Bayer’s statin Baycol had to be withdrawn after a string of fatalities were reported. Bayer went on to pay out billions in settlements. But the statin empire rolled on, stronger than ever.
And that brings us back to the heart of the story.
Statins were sold as “life insurance for your arteries.” Doctors were told to hand them out to anyone with heart disease, anyone with diabetes, and anyone with a slightly elevated LDL – a goal post number that has continued to move all over the place over the years as you may have noticed. Within two decades, statins became the #1 prescribed class of drugs worldwide, and by the 2000s, nearly 100 million Americans were drinking the Kool-Aid – or in this case, the Lipitor.
Here’s the genius situation:
• Cholesterol is something we all have.
• Heart disease is the #1 cause of death.
• If statins lowered cholesterol and lower cholesterol decreased heart disease well, then, statins they’re for life.
That’s not a cure, folks. That’s a brilliant business strategy.
The 2022 Meta-Analysis Bombshell
Now, fast-forward to 2022. A massive meta-analysis – published in JAMA Internal Medicine – looked at decades of randomized controlled trials, the gold standard of evidence. This was supposed to be the big vindication: proof that statins save lives.
Instead, what it showed was… what?
Here’s the data:
- All-cause mortality reduction: a measly 0.3–0.4%.
- Heart attack risk reduction: about 0.7% absolute benefit.
- Stroke reduction: small, not statistically significant.
- And most shocking? The degree of LDL lowering had no reliable correlation with actual clinical outcomes.
Bottom line: For every 100 people who take a statin for 5 years, maybe one or two avoid a heart event. One or two.
Did I fail to mention? Those weren’t fatal events. No mice, rabbits, or humans died during the making of this meta-analysis. These minuscule benefits came from preventing non-fatal heart attacks and strokes. Statins didn’t move the needle on whether you lived or died but they did have measurable findings – you know, increase incidence of diabetes, muscle pain, muscle breakdown, memory loss, you know.
That’s like bragging your car’s safety rating is great because you only broke your leg in the crash instead of dying. Technically true, but not exactly the miracle cure you were sold.
The Statistical Scam: How They Cooked the Books
If you’ve ever wondered how statins became the world’s most prescribed drug despite unimpressive benefits, the answer is simple: statistical smoke and mirrors.
As Mark Twain famously said,‘There are three kinds of lies: lies, damned lies, and statistics.’ And nowhere is that truer than in statin research.
Most of the original statin trials didn’t headline with absolute risk reduction – these are the real-world numbers that matter. Nope. They used something called relative risk reduction, which sounds scarier, splashier, and sells way more prescriptions.”
Example #1 – Relative vs. Absolute Risk
- Let’s say we have a Patient with a 10% risk of having a heart attack over the next 10 years.
- A study finds that Statin use reduces that risk to 7%.
The Absolute risk reduction: 3%. Meh.
The Relative risk reduction: 30%. How did we get there? OK – Take 10% minus 7% divided by 100% and all of a sudden you have the following headline that hit and has stuck for eternity: “Statins reduce heart attack risk by 30%!”
One group has a 10% risk. The other has a 7% risk (determined by an industry funded study, remember) – authors can report this out as either a 3% absolute risk reduction OR a 30% relative risk reduction. Same data. Different spin. One sells prescriptions, the other makes people yawn. Benefits are reported as relative risk and harms as absolute risks – got me? OK, let’s do one more.
Example #2 – The JUPITER Trial (2008)
- JUPITER was the big rosuvastatin (Crestor) trial, stopped early at just under 2 years because….
• Reported headline: “44% reduction in cardiovascular events!”
Sounds miraculous, right? Let’s do the math.
- Event rate in placebo: 1.36 per 100 person-years.
- Event rate in statin group: 0.77 per 100 person-years.
- That gives a hazard ratio of about 0.56.
- Subtract that from 1 and voilà: 1 − 0.56 = 44% relative risk reduction.
But here’s what really happened:
- The absolute numbers dropped from about 1.8% to 0.9%.
- That’s an absolute risk reduction of ~0.9%.
So yes – relative risk says “44% lower risk!”
Absolute risk says “less than 1% difference.”
That means you’d need to treat more than a hundred people for almost two years to prevent one non-fatal event. So the 44% miracle cure? In reality, less than 1% of people actually benefited. Maybe. The rest just got the side effects.
Remember this is the best of the best – data from industry funded trials where they threw out outliers and patients with side effects during their ‘run-in’ period.
That’s like testing a new car, removing every vehicle on the road that could possibly crash into it, and then bragging, ‘Look, our safety rating is perfect!’ If you did that in any other industry, you’d be sued. And probably sent to jail. In medicine? You get published in The Lancet.
Whistleblowers Speak
Now, if you think I’m the only one saying this – that statins aren’t the miracle pill you’ve been promised – think again. A few brave cardiologists have been out there waving the red flag for years, and like me, they get called quacks, fringe, ‘anti-science.’ Tin foil hat wearing freaks – But let’s actually hear what they’ve got to say.
Clip: Paul Mason – The shady truth about statins
‘Millions of people around the world taking statins will derive absolutely no benefit from them, with the very real possibility of harm.’
“You hear that? Millions on statins… with no benefit. That’s not me talking, that’s Dr. Paul Mason, an Australian physician who actually reads the data instead of the Pharma press releases. He’s saying what most doctors suspect in the back of their minds but are too scared to admit out loud: this whole statin story has been oversold, overhyped, and overprescribed.”
Clip: Aseem Malhotra – Debunking Statins
‘Patients are not given informed consent, because they’re never told the true absolute benefit. If they were, most would never take a statin.’
And there it is – Aseem Malhotra, a UK cardiologist who’s been dragged through the mud for saying exactly this: patients are not told the real numbers. They’re told the relative risk reduction fairy tale – the ‘30% lower risk!’ headline – while the absolute benefit is less than 1%.
So when you put it all together – the cooked stats, the industry-funded trials, the patients with side effects quietly excluded, and the cardiologists willing to risk their careers to tell the truth – you start to realize this isn’t fringe at all. This is the quiet part said out loud.
And if you’re thinking, ‘Well, surely my doctor knows all this’… let me save you the suspense: they probably don’t. Or if they do, they’re stuck in a system that rewards the prescription, not the prevention.
The Side Effect Story
Now, statin defenders will tell you side effects are “rare.” You know, because they pulled people who had them out of the trials. But ask real-world patients and you’ll hear the real story.
- Muscle aches and weakness: reported in up to 25% of statin users.
- Fatigue and low energy: common enough that patients often quietly stop their meds.
- Cognitive complaints: memory lapses, brain fog. Research is mixed, but patients swear by the connection.
- Liver toxicity: not everyday common, but very real — check the warning labels.
And then there’s diabetes.
The Women’s Health Initiative – a massive study of postmenopausal women of over 161,00 women studying hormones and not statin side effects, but whatever – data is data – found that statin use was associated with a 48% increased risk of developing diabetes. And depending on the statin and baseline risk factors, that number climbed as high as 71%.
Let’s pause there for a second. A drug that’s supposed to ‘protect your heart’ is literally giving women diabetes at rates fifty to seventy percent higher than non-users. That’s not a rare side effect — that’s a disaster. The number one risk factor for heart disease is….DIABETES.
If we measured harms the way Big Pharma measures benefits – using that same “relative risk” trick – the numbers would flip the narrative. You’d find statins are more likely to cause diabetes, memory loss, or liver toxicity than they are to prevent a heart attack or stroke.
And that’s exactly the point Dr. Paul Mason often makes. Let me give you two jaw-dropping examples.
- The Survival Math (BMJ Open, 2015): After years of statin therapy, patients gained an average of just 3–4 extra days of life. Not years, not months – days.
- The Memory Loss Study (JAMA Internal Med, 2015): Within 30 days of starting a statin, patients were over 300% more likely to report memory problems compared to controls. Adjust for confounders, and you’re looking at a roughly 400% increased risk of memory impairment.
So let’s line this up. A few days of extra survival… versus a 3–4x higher chance of losing your memory, plus a 50–70% higher chance of developing diabetes. That’s not prevention — that’s a bad trade deal.
Imagine the ad copy if they were honest: ‘This drug is more likely to wreck your blood sugar or memory than it is to save your life.’ Not quite as sexy as ‘30% risk reduction,’ is it?
The Golden Goose in Plain Sight
So why go through all the hassle of cooking the books, rigging the studies, fixing the results? Go ahead, you know the answer, don’t be shy – money.
Lipitor alone made Pfizer over $130 billion before its patent expired. Statins as a class raked in tens of billions every year.
And when patents ran out? Pharma didn’t quit – they pivoted:
- Push “high-intensity” statins.
- Keep lowering LDL “target goals.”
- Stack guideline committees with “experts” who had financial ties.
Result? Millions more people suddenly “qualified” for lifelong prescriptions.
And here’s why doctors still play along: it’s easy. LDL high? Prescribe. LDL low? Good job. Insurance companies reward compliance. Patients are terrified of cholesterol. It’s not thoughtful medicine – it’s checkbox medicine.
So let’s connect the dots:
- Statins are cheap to make.
- They target something everyone has (cholesterol).
- They require lifelong use.
- They give doctors the illusion of “doing something.”
Statins aren’t just drugs – they’re the blueprint. Find a universal lab marker, make people afraid of it, and sell them a pill for life.
Why We Need to Reevaluate Statins in Medicine
So the next time someone tries to scare you with your LDL number, remember this: statins aren’t a miracle drug. They’re a marketing miracle. A trillion-dollar Golden Goose built on spin, guidelines, and fear.
The emperor has no clothes, my friends.
And if cholesterol isn’t the real villain, what is? Next time, we’ll talk about the fire that actually fuels heart disease: metabolic syndrome, inflammation, and oxidative stress.
And trust me—once you see the real culprit, you’ll never look at a statin the same way again.
